Suppr超能文献

冈本自发性高血压大鼠肾组织激肽释放酶的个体发生学研究:与人类高血压肾病的比较。

An ontogenic study of renal tissue kallikrein in Okamoto spontaneously hypertensive rats: comparisons with human hypertensive nephropathy.

作者信息

Figueroa C D, Bhoola K D, MacIver A G, Mackenzie J C

机构信息

Department of Pharmacology, Medical School, University of Bristol, U.K.

出版信息

Nephrol Dial Transplant. 1992;7(6):516-25.

PMID:1320231
Abstract

Urinary excretion of tissue kallikrein is reduced in essential hypertension. Although a similar finding has been reported in spontaneously hypertensive rats (SHR), only a few studies have been concerned with the amount of enzyme within the kidney both at the time of onset and during progression of the hypertension. We have performed an ontogenic study on the renal parenchymal values and immunoreactivity of tissue kallikrein in Okamoto SHR aged 4-78 weeks. Additionally, these two parameters were analysed in human biopsies taken from patients with hypertensive nephropathy. The enzymatic activity of renal tissue kallikrein (active and total; specifically antagonized by anti-tissue kallikrein antibodies), increased from 4 to 52 weeks in SHR when compared to normotensive Wistar Kyoto (WKY) rats; this increase was associated with a significant increase in blood pressure. In contrast, 78 weeks SHR and human biopsy tissue showed a substantial reduction in tissue kallikrein values. Also, both renal tissues showed a reduction in immunoreactivity in the cells of the connecting tubules that specifically store the enzyme. In advanced hypertension the observed reduction in tissue kallikrein was probably secondary to a loss of distal tubular mass, as a result of tubular atrophy and fibrosis. The greater values for renal tissue kallikrein in the kidney and reported reduced urinary excretion during the early phases of spontaneous hypertension may be explained by a primary defect in the mechanisms that regulate release of tissue kallikrein from the connecting tubule cells.

摘要

原发性高血压患者尿组织激肽释放酶排泄减少。尽管在自发性高血压大鼠(SHR)中也有类似发现,但仅有少数研究关注高血压发病时及进展过程中肾脏内该酶的含量。我们对4至78周龄的冈本SHR肾实质中组织激肽释放酶的含量及免疫反应性进行了个体发育研究。此外,还对取自高血压肾病患者的人体活检组织中的这两个参数进行了分析。与正常血压的Wistar Kyoto(WKY)大鼠相比,SHR肾组织激肽释放酶的酶活性(活性和总活性;可被抗组织激肽释放酶抗体特异性拮抗)在4至52周时增加;这种增加与血压显著升高相关。相反,78周龄的SHR和人体活检组织显示组织激肽释放酶含量大幅降低。此外,两种肾组织中特异性储存该酶的连接小管细胞的免疫反应性均降低。在晚期高血压中,观察到的组织激肽释放酶减少可能继发于远端肾小管质量的丧失,这是肾小管萎缩和纤维化的结果。自发性高血压早期肾脏中肾组织激肽释放酶含量较高且尿排泄减少,这可能是由于调节连接小管细胞释放组织激肽释放酶的机制存在原发性缺陷所致。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验